Quick Overview: Dr. Carol Routledge, Chief Medical and Scientific Officer at Welcome to the Psychedelic Spotlight podcast. In this episode, the Psychedelic Investor sits down with Dr. Carol Routledge, Chief ... "Psychedelics for Depression" — The DMT Conference — Peter Rands, CEO Small Pharma Ltd.

Small Pharma Study Of Dmt - Detailed Overview & Context

Dr. Carol Routledge, Chief Medical and Scientific Officer at Welcome to the Psychedelic Spotlight podcast. In this episode, the Psychedelic Investor sits down with Dr. Carol Routledge, Chief ... "Psychedelics for Depression" — The DMT Conference — Peter Rands, CEO Small Pharma Ltd. Psychedelic therapy could bring the ancient healing powers of drugs like Investors in the psychedelics space may have only just heard of the UK-based Join us for an insightful episode featuring Dr. Carol Routledge, a distinguished senior scientist and the Chief Medical and ...

Dr. David Erritzoe, Chief Investigator of

Photo Gallery

Small Pharma - Study of DMT for Treatment of Major Depressive Disorder
Small Pharma kicks off its Phase II study of DMT-and-psychotherapy treatment to treat depression
Small Pharma On DMT Phase 1 Completion
Small Pharma on conducting world’s first clinical trials for psychedelic DMT and listing in Canada
$DMT is Invested in Healing | Peter Rands, CEO Small Pharma | DMT Conference | Microdose
Peter Rands, CEO of Small Pharma, on DMT and Parliament
Algernon Pharmaceutical’s preclinical study of DMT for stroke confirms growth of Neurons by 40%
Can DMT Treat Depression?
"Psychedelics for Depression" — The DMT Conference — Peter Rands, CEO Small Pharma Ltd.
DMT: Is it the best new treatment for depression? | Just Might Work | Freethink
Algernon Pharmaceuticals completes manufacturing of Psychedelic Drug DMT for Phase 1 and 2 study
‘Small Pharma Was Established to Make Medicine’ – Peter Rands, Director and CEO
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored